By John S. MacNeil

“Am I suggesting that all NIH researchers become drug developers?” asked Francis Collins at the annual BIO meeting this summer. Although he answered himself with an emphatic “No!”, that he asked the question at all is noteworthy. In a paper published in Nature last April, Collins first raised the idea of the National Human Genome Research Institute participating more actively in early-stage drug discovery. At BIO he made the institute’s plans more explicit.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Lawmakers have asked four direct-to-consumer genetic testing companies to explain their privacy policies and security measures, according to Stat News.

The Trump Administration has proposed a plan to reorganize the federal government, the Washington Post reports.

In Science this week: genetic overlap among many psychiatric disorders, and more.

The Economist writes that an increasing number of scientific journals don't do peer review.